Novavax

Novavax, Inc. is a pioneering biotechnology company dedicated to combating serious infectious diseases around the globe through the innovative development of vaccines. With a robust commitment to public health, Novavax focuses on creating transformational vaccines that address some of the world’s most pressing health challenges. Their advanced pipeline features the Matrix-M™ adjuvant technology and recombinant nanoparticle vaccine technology, which enhance immune responses to provide broader and more effective protection.

Novavax is not only focused on vaccine discovery but is also dedicated to facilitating equitable access to these vital health solutions. Their research efforts have recently led to the introduction of the R21/Matrix-M™ Malaria vaccine, a significant breakthrough set to benefit children in Africa. By leveraging years of scientific research and innovations, Novavax aims to ensure a safer and healthier future worldwide, while also maintaining high standards in environmental, social, and governance practices.